TG Therapeutics and Rhizen Pharmaceuticals have partnered to develop and commercialise Rhizen’s PI3K delta inhibitor, TGR-1202, previously known as RP5264.

Under the collaboration, which will initially focus on hematologic malignancies and autoimmune disease indications, the companies will jointly develop the product on a worldwide basis, excluding India.

Rhizen will contribute backup molecules, enabling TG to develop differentiated therapies against hematologic cancers and autoimmune diseases.

TG Therapeutics executive chairman and interim CEO Michael S Weiss said the company has entered into collaboration with Rhizen due to their innovative pre-clinical development program, which has yielded an impressive portfolio of PI3K delta inhibitors.

"TGR-1202 has already demonstrated encouraging pre-clinical activity, and will serve to expand our pipeline as we seek to develop much needed therapies for patients suffering from hematologic malignancies," Weiss said.

Under the agreement, TG will cover the costs of clinical development up to Phase II, after which the companies will be jointly responsible.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Rhizen is eligible to receive upfront, development, and commercialisation milestone payments in addition to royalties tied to net sales, the aggregate of which is expected to exceed $250m.

Rhizen president Swaroop Vakkalanka said; "The deep clinical and regulatory development knowledge and experience of the team at TG Therapeutics, and the existing clinical program focused on B-cell malignancies, makes TG an ideal partner with which to collaborate on development of TGR-1202."

Rhizen will maintain rights to manufacture and supply the product to TG Therapeutics, which will be responsible for all clinical and regulatory development for TGR-1202.